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Abstract 1 
Adrenal incidentalomas constitute a common clinical problem with an overall prevalence of around 2-2 
3%, but are more common with advancing age being present in 10% of those aged 70y. The majority 3 
of these lesions are benign adrenocortical adenomas (80%), characterized in 10-40% of the cases by 4 
autonomous cortisol hypersecretion, and in 1-10% by aldosterone hypersecretion. Several 5 
observational studies have shown that autonomous cortisol and aldosterone hypersecretion are more 6 
prevalent than expected in patients with osteopenia and osteoporosis: these patients have accelerated 7 
bone loss and an increased incidence of vertebral fractures. In contrast to glucocorticoid action, the 8 
effects of aldosterone on bone are less well understood. Recent data, demonstrating a concomitant co-9 
secretion of glucocorticoid metabolites in patients with primary aldosteronism, could explain some of 10 
the metabolic abnormalities seen in patients with aldosterone hypersecretion. 11 
In clinical practice, patients with unexplained osteoporosis, particularly when associated with other 12 
features such as impaired glucose tolerance or hypertension, should be investigated for the possible 13 
presence of autonomous cortisol or aldosterone secretion due to an adrenal adenoma. Randomized 14 
intervention studies are needed, however, to investigate the optimum interventions for osteoporosis 15 
and other co-morbidities in these patients. 16 
 17 
Keywords: adrenal, incidentaloma, autonomous cortisol hypersecretion, primary aldosteronism, bone, 18 
osteoporosis.  19 
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Introduction 21 
The term adrenal incidentaloma refers to any clinically unsuspected adrenal lesion that is detected 22 
incidentally during imaging for other indications [1,2]. With widespread use of imaging techniques, 23 
adrenocortical incidentalomas constitute a common clinical problem with a prevalence of more than 24 
10% in people 70 years or more [1-6]. Adrenal incidentalomas can be benign or malignant, 25 
functioning or nonfunctioning, unilateral or bilateral. The vast majority are benign adrenocortical 26 
adenomas (ACA, 80%) [1,2] with the most frequent endocrine dysfunction being ‘autonomous cortisol 27 
hypersecretion’, previously termed ‘subclinical Cushing’s syndrome’ [1,2,7-10], while primary 28 
aldosteronism (PA) seems to be the most frequent hormonal secretion in Korean population with 29 
adrenal incidentaloma [11]. Depending on definitions used, the prevalence of excess cortisol secretion 30 
amongst these adrenocortical lesions ranges from 10-40%. In contrast, the frequency of aldosterone 31 
hypersecretion varies from 1% to 10% according to various tests used [1,2,6,12,13]. Recent data, 32 
however, indicate that excess cortisol secretion is also seen in PA, and that this may account for some 33 
of the metabolic abnormalities seen in these patients [14]. Furthermore, the cut-off used to define 34 
whether an adrenocortical incidentaloma is ‘functioning’ or ‘non-functioning’ is important, since 35 
patients with apparently non-nonfunctioning adrenal incidentalomas, as defined by a serum cortisol 36 
post dexamethasone of <1.8 ug/dL, still have excess risk of what may be reasonably considered to be 37 
cortisol-dependent co-morbidities [15].  38 
The estimated cost of fragility fracture in the UK was £2.3 billion in 2011, but with this rising to a 39 
predicted cost of £6 billion by 2036, mostly due to the cost of hip fracture [16]. Bone loss and 40 
osteoporosis are well-established complications of glucocorticoid excess, be it from endogenous 41 
Cushing’s syndrome or exogenous sources [17]. Given the wide prevalence of adrenal incidentaloma 42 
with low-grade cortisol-excess (1-4% of the ageing population), it is important to understand what 43 
effect there may be on bone health, as this may have a very significant impact at the population level. 44 
In light of this, many studies over the past two decades have sought to investigate the effect of 45 
subclinical hypercortisolism on bone health in patients with adrenal incidentalomas. 46 
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The aim of this article is to outline the known effects of cortisol and aldosterone on bone and 47 
summarize the main studies that have assessed bone health in patients with adrenal incidentalomas.  48 
 49 
Methods 50 
A literature search was conducted in PubMed in English language, in order to identify publications on 51 
adrenal incidentalomas and bone until the end of June 2018. We collected, analyzed and qualitatively 52 
resynthesized data regarding the effects cortisol and aldosterone on bone metabolism, as well as 53 
studies that have assessed bone health in patients with adrenal incidentalomas. We present in turn 54 
updated information regarding the mechanisms of action of cortisol and aldosterone on bone and 55 
clinical evidence from patients with adrenal incidentalomas with autonomous cortisol hypersecretion 56 
or hyperaldosteronism or both. We also discuss clinical implications and provide recommendations on 57 
appropriate management. 58 
 59 
Cortisol hypersecretion and bone. 60 
Effects of cortisol on bone metabolism: mechanisms of action. 61 
Glucocorticoids are important for bone development by affecting osteoblast differentiation [18,19], but 62 
excessive quantities seem to have a negative impact on bone health [20] and this impact will be 63 
analyzed here. In patients with adrenal incidentalomas with increased secretion of glucocorticoid to 64 
levels insufficient to cause classic Cushing’s syndrome, the ‘sub-clinical’ levels may still be sufficient 65 
to increase the risk of vertebral fractures due to a decrease of bone mineral density (BMD) and bone 66 
quality [20,21]. 67 
Evidence showing the effect of glucocorticoid on bone deriving primarily from in vitro and in vivo 68 
models of mouse treated with glucocorticoid. Osteoporosis induced by glucocorticoid excess is due 69 
mainly to a direct effect on cells involved in bone remodelling (osteoblast, osteocytes, osteoclast and 70 
their precursors) [20], which express the glucocorticoid receptors (GRs) that mediated the main action 71 
of cortisol [22]. The principal effect of the cortisol excess is a reduction of bone formation through a 72 
suppression of osteoblast activity mediated by an upregulation of peroxisome proliferator-activated 73 
receptor (PPAR)-γ [23] and an inhibition of the wingless (wnt)/β-catenin signaling pathway (Fig. 1) 74 
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[24-26]. These mechanisms favor the differentiation of mesenchymal progenitors to adipocytes instead 75 
of osteoblasts, resulting in a decreased number of osteoblasts and in an increasing of osteoblast 76 
apoptosis [27,28]. Cortisol excess stimulates the expression in osteocytes of sclerostin which seems to 77 
be a key role in the inhibition of the wnt pathway in osteoblast (Fig.1) [29,30]. In mouse models of 78 
glucocorticoid-induced osteoporosis it has been showed that the treatment with anti-sclerostin 79 
antibody prevented the reduction of bone mass and strength in comparison to placebo [30]. Moreover, 80 
the treatment with these antibodies prevented osteocytes from apoptosis in rodents [31]. The 81 
suppression of osteoblasts differentiation associated with an increased osteoblasts and osteocytes 82 
apoptosis causes a reduction of bone formation (Fig.1).  83 
Cortisol excess favors also bone resorption through an alteration of the receptor activator for NF-B 84 
ligand (RANKL)/osteoprotegerin (OPG) ratio produced by osteoblasts and osteocytes (Fig.1) [32-34]. 85 
RANKL is a regulator of recruitment, activation and survival of osteoclasts, whereas, OPG acts as a 86 
decoy receptor for RANKL preventing its interaction with RANK and causing the inhibition of 87 
osteoclastogenesis [35]. An in vivo mouse model demonstrated that glucocorticoids treatment 88 
decreased  secretion of OPG rather than elevating RANKL expression in osteocyte cells [34]. The 89 
modified RANKL/OPG ratio by cortisol increases the RANKL activity and promotes the bone 90 
resorption (Fig.1) [32-34]. Moreover, glucocorticoids stimulate the production of the macrophage 91 
colony-stimulating factor (M-CSF) that stimulates osteoclastogenesis together with RANKL [36]. 92 
However, this effect of bone resorption is only transient and usually decreases over time due to a 93 
suppression of osteoblasts and osteocytes activity [37]. Therefore, the decrease in bone formation 94 
rather than increase in bone resorption plays a key role in osteoporosis induced by cortisol excess 95 
[28,19]. 96 
It should be noted that the severity of the skeletal effect of hypercortisolism could due to individual 97 
sensitivity to cortisol that may modify the overall phenotype observed. Some of the variability in 98 
sensitivity in different tissues in the same individual may be mediated by the repertoire of co-99 
activators and co-repressors that are present in a given tissue. Moreover, evidence suggests that at least 100 
some of the variable sensitivity to glucocorticoids in bone is conferred by polymorphisms of the GR 101 
[38]. Moreover, local regeneration of cortisol by 11-beta hydroxysteroid dehydrogenase type 1 102 
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(11HSD1) may contribute further to these effects [39]. 103 
Hypercortisolism influences mineral and bone metabolism also through indirect effects mediated by 104 
calcium (Ca++) and parathyroid hormone (PTH) [20]. Cortisol reduces intestinal Ca++ absorption and 105 
increases renal Ca++ excretion, with a final Ca++ negative balance that may deteriorate bone 106 
mineralization. Opposing date are reported regarding PTH levels, a marker of bone resorption, in 107 
patients with adrenal incidentaloma and. Two studies by the group of Chiodini showed that in 108 
female patients with adrenal incidentaloma autonomous cortisol hypersecretion and 109 
autonomous cortisol hypersecretion had higher PTH levels in comparison to patients with 110 
inactive adrenal masses [40,41]. Higher levels of PTH in these patients were not shown by 111 
studies from other groups [42,43]. However, regardless of an increase plasma levels, PTH 112 
correlated inversely with femoral BMD [40,42,43]. More consistently observed are lower 113 
blood osteocalcin levels, a marker of bone formation, in patients with autonomous cortisol 114 
hypersecretion in comparison to patients with inactive adrenal incidentaloma or healthy 115 
controls [41,40,42,44]. The decrease of osteocalcin levels is due to the inhibition of 116 
osteoblastic activity and increase of osteoblastic apoptosis caused by cortisol excess [20]. 117 
However, this finding was not confirmed by other studies [43,45]. It is important to note that 118 
the discordance observed between studies on PTH and osteocalcin levels is likely due to the 119 
small sample size of the studies and the different criteria used for the definition of 120 
autonomous cortisol hypersecretion [21].  121 
Taken together, it is clear that the overall level of cortisol secretion needed to have deleterious effects 122 
differs by tissue and by individual, but that over time even subtle increases of endogenous cortisol 123 
secretion has a net effect favoring bone loss. 124 
 125 
Clinical evidence from patients with adrenal incidentaloma and autonomous cortisol 126 
hypersecretion. 127 
Evidence for the effect of cortisol hypersecretion on bone health also comes from clinical studies too. 128 
Although glucocorticoids impair bone turnover with inhibition of osteoblastic activity [42,46,40], in 129 
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patients with adrenal incidentalomas initial BMD studies did not find significant differences between 130 
those deemed to have autonomous cortisol secretion and controls [40,47,48]. Two studies assessing 131 
more homogeneous populations with adrenal incidentalomas, one including eugonadal males [45] and 132 
one including post-menopausal women [43], demonstrated significantly decreased BMD in patients 133 
with autonomous cortisol hypersecretion compared to those without. This decrease was however, 134 
mainly within the limits of osteopenia and not sufficient to be classed as osteoporosis [43].  135 
Several observational studies from one Italian center provide data that autonomous cortisol 136 
hypersecretion in patients with ACA is associated not only with accelerated bone loss but also with 137 
increased incidence of vertebral fractures [49-51]. Chiodini et al. included only women (70 patients 138 
and 84 controls) to avoid gender-related effects on bone and divided participants according to 139 
premenopausal and postmenopausal status. Subclinical hypercortisolism was associated with higher 140 
prevalence of fractures and reduced volumetric bone mass at the lumbar spine, independent of gonadal 141 
status. BMD, however, was mainly affected by menopausal status [49]. Another retrospective study 142 
including 287 patients with adrenal incidentalomas and 194 controls, showed that BMD was 143 
significantly lower in lumbar spine and femoral neck in patients with autonomous cortisol 144 
hypersecretion than nonfunctioning adenoma and controls. Fracture prevalence and spinal deformity 145 
index were also significantly higher in those with subclinical hypercortisolism regardless of age, 146 
gender, menopausal status and BMD [50]. In a prospective study by the same group, 103 consecutive 147 
patients with adrenal incidentalomas were followed-up in order to evaluate the fracture risk over time. 148 
It was shown that the group of patients with autonomous cortisol hypersecretion had a higher rate of 149 
vertebral fractures (82%) compared to baseline (56%), regardless of age, gender, body mass index 150 
(BMI), BMD and menopause, and this incidence was higher than that seen in patients with 151 
nonfunctioning adrenal incidentalomas [51]. It is likely that the fractures reported in these studies are 152 
being disclosed by very sensitive methodologies, since in routine clinical practice such a high rate of 153 
clinically significant fractures is not usually seen. 154 
Interestingly, fracture risk was not directly predicted by BMD, as 40% of fractures occurred in patients 155 
with normal or only slightly reduced BMD [50,51]. Therefore, it is possible that both bone mass and 156 
bone quality may be disordered. In further study from the same group, bone microarchitecture was 157 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6 
 
assessed by measurement of the trabecular bone score (TBS) in patients with adrenal incidentalomas 158 
and concluded that bone quality in autonomous cortisol hypersecretion is altered [52]. Furthermore, it 159 
was shown that a combination of low TBS and low BMD was highly predictive for fractures, whilst 160 
the converse was true for those with a normal TBS plus high BMD, in whom a lower rate of fractures 161 
was observed [52]. A very recent study provided evidence that patients with mild autonomous cortisol 162 
secretion presented significantly decreased trabecular bone score (TBS), but not BMD when compared 163 
with patients with non-secreting incidentalomas [53]. TBS may be proved as a promising, non-164 
invasive, inexpensive tool for the routine assessment of these patients in clinical practice. 165 
A meta-analysis including six relevant studies has shown that patients with bilateral ACA had a higher 166 
prevalence of autonomous cortisol hypersecretion compared to patients with unilateral incidentalomas 167 
of the same size as the largest of the bilateral adenomas [54]. Only one study from this analysis 168 
investigated bone parameters in patients with unilateral vs. bilateral adrenal incidentalomas and 169 
reported a higher prevalence of fractures in those patients with bilateral adenomas. Interestingly, this 170 
higher prevalence remained significant even after adjusting for subclinical hypercortisolism, BMI, age 171 
and lumbar spine BMD [55]. 172 
When managing patients with adrenal incidentaloma in clinical practice, it would be very useful to 173 
know which biochemical parameter of cortisol hypersecretion is the most reliable for predicting 174 
increased fracture risk. However, this is difficult as the diagnosis of autonomous cortisol secretion 175 
itself is still a matter of debate [56]. It is worth noting that the Italian group with the most studies on 176 
the topic is based on the presence of two out of the following three alterations for the diagnosis of 177 
subclinical hypercortisolism: 1) increased urinary free cortisol (UFC) levels (>193.1 nmol/24 h) 2) 178 
unsuppressed serum cortisol levels after 1-mg overnight dexamethasone (Dex) suppression test (serum 179 
cortisol after Dex > 82.8 nmol/liter), and 3) low ACTH levels (<2.2 pmol/liter) [45,43,49-52].  180 
A recent study from Italy found that serum cortisol levels after 1 mg dexamethasone-suppression test 181 
greater than 2.0 mg/dL (55 nmol/L) are independently associated with both prevalent and incident of 182 
vertebral fracture as well as with an increased risk of new vertebral fractures at diagnosis and during 183 
follow-up [57]. This association between the degree of biochemical cortisol hypersecretion and the 184 
risk for vertebral fracture was expected and is in accordance with previous studies, most of which 185 
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come from a single Italian group [45,43,49-52]. Interestingly, this association was independent of 186 
BMD and supports the notion that reduced bone quality is the most significant parameter leading to 187 
skeletal fractures as a consequence of cortisol excess [52]. 24-h urinary free cortisol and plasma 188 
adrenocorticotropic hormone (ACTH) levels were shown to be not statistically associated with fracture 189 
risk. A potential explanation for plasma ACTH not being a useful marker is the differing sensitivity of 190 
various tissues to glucocorticoids: bone tissue may be affected even before suppression of 191 
hypothalamic-pituitary-adrenal axis is evident [57]. 192 
Surgical treatment of ACA in small groups of patients with autonomous cortisol hypersecretion has 193 
been associated with improvement of various parameters, including weight, blood pressure, glucose 194 
and lipid metabolism [58,59]. However, here the data are still too limited, and some studies report no 195 
benefit. The European guidelines on the management of adrenal incidentaloma recommend 196 
adrenalectomy only in the minority of cases, and based on careful individualised treatment decisions. 197 
Recent data showed a 30% reduction of vertebral fracture risk after adrenalectomy in selected patients 198 
[60]; this finding is potentially important and underlines the pathophysiological association between 199 
cortisol hypersecretion, reduced bone quality and fractures in patients with ACA. However, it is 200 
important to note that the majority of studies on bone in patients with adrenal incidentaloma come 201 
from one group [49,50,58,45,57,51,55] and before making wide-ranging treatment recommendations it 202 
is crucial to have larger studies in various populations.  203 
 204 
Primary aldosteronism and bone. 205 
Effects of aldosterone on bone metabolism: mechanisms of action. 206 
Contrary to the well-studied mechanisms, which underline the link between autonomous cortisol 207 
secretion and bone, less is known regarding the link between hyperaldosteronism and osteoporosis. 208 
Over the last two decades, several small studies have demonstrated that aldosterone excess is likely to 209 
affect bone turnover through a direct effect on bone cells and through indirect mechanisms via PTH 210 
and oxidative stress [61-66] (Fig. 2). 211 
The direct effect of aldosterone on bone metabolism is still poorly understood. Mineralocorticoid 212 
receptors (MRs) are expressed in human and rat osteoclasts, osteocytes and osteoblasts [67,68], 213 
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suggesting a direct effect of aldosterone on bone turnover. MRs are present also in normal and 214 
adenomatous parathyroid tissue [69,70]. Furthermore, a positive association between the 215 
aldosterone/renin ratio and serum PTH concentration has been demonstrated in normal individuals 216 
[71], suggesting that aldosterone may directly regulate PTH synthesis and secretion (Fig. 2). 217 
Moreover, in vivo and observational human studies suggest that MR antagonists (MRA) have a 218 
beneficial effect on bone metabolism. In rat models, treated with aldosterone and salt for 4-6 weeks, 219 
bone loss was attenuated after administration of the MRA spironolactone [72,73,61]. Similarly, 220 
patients with PA treated with spironolactone showed decreased urinary calcium loss and improved 221 
BMD [74-76]. However, a recent single-center, double-blind, randomized, placebo-controlled trial 222 
demonstrated no effects of eplerenone on bone turnover markers in patients with primary 223 
hyperparathyroidism, suggesting that MR antagonism may not be relevant in primary 224 
hyperparathyroidism, but could have efficacy in condition of hyperparathyroidism secondary to 225 
hyperaldosteronism [77]. 226 
The interaction between MR and bone has been further examined in animal models. In rats treated 227 
with aldosterone and salt, there was a significant increase in urinary and fecal excretion of Ca++ and 228 
magnesium (Mg++), with a consequent progressive reduction of plasma ionized Ca++ and Mg++ levels 229 
[61]. Urinary losses of Ca++ and Mg++ were the result of expanded extravascular fluid volume resulting 230 
in decreased resorption of sodium (Na+), Ca++ and Mg++ in the proximal tubule of the nephron with a 231 
consequent increase of their excretion in the distal tubule. Because aldosterone stimulates Na+ 232 
resorption, but not that of Ca++ and Mg++  at the distal tubule, this causes a marked increase of Ca++ and 233 
Mg++ excretion [78,79], with the lowering of Ca++ and Mg++ leading to secondary 234 
hyperparathyroidism, stimulating bone resorption and a significant reduction of BMD and cortical 235 
bone strength (Fig. 2) [61,80]. 236 
In the same rat model, a significant reduction of plasma α1-antiprotease activity and an increase of 237 
lymphocyte hydrogen peroxide production was reported after aldosterone-sodium treatment for 1-6 238 
weeks in comparison to control group [61,80,81]. The authors hypothesized that aldosterone promotes 239 
a systemic condition of oxidative stress and inflammation that could result in increased osteoblast and 240 
osteocyte apoptosis, and reduced bone formation (Fig. 2) [82,83].  241 
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In conclusion, hyperaldosteronism affects bone turnover through several direct and indirect 242 
mechanisms, most of which act through an increase of serum PTH levels. 243 
 244 
Clinical evidence from patients with adrenal incidentaloma and hyperaldosteronism. 245 
Evidence regarding the link between hyperaldosteronism and bone metabolism is also derived from 246 
several observational studies. Aldosterone hypersecretion can be detected in 1-10% of patients with 247 
adrenal incidentalomas [1,2]. Together with bilateral adrenal hyperplasia (BAH), the aldosterone-248 
producing adenomas (APA, also termed ‘Conn adenoma’) represent more than 90% of cases of PA; 249 
the remaining cases of PA are due to unilateral adrenal hyperplasia and aldosterone-producing 250 
carcinoma [84]. Several observational studies showed significantly higher PTH levels, lower serum 251 
Ca++ levels and higher urinary Ca++ excretion in patients with PA in comparison to those with essential 252 
hypertension (EH) [63,64,85,74,86,87], and a higher prevalence of osteoporosis [63,64,66,65,88,74]. 253 
Salcuni et al. reported the first association between hyperaldosteronism and osteoporosis in patients 254 
with APA [63]. In 11 patients with APA there was decreased BMD at the lumbar spine, total and 255 
femoral neck (13%, 8% and 11%, respectively), an increased prevalence of osteoporosis (73 vs. 20%) 256 
and a higher incidence of vertebral fractures (46 vs. 13%), in comparison to 15 patients with 257 
nonfunctioning incidentalomas. Moreover, the increased urinary Ca++ excretion and elevated PTH 258 
levels found in APA patients were reversed after adrenalectomy or spironolactone treatment [63].  259 
The reversibility of secondary hyperparathyroidism in PA patients after surgical or medical treatment 260 
was supported by two other observational studies [85,86]. Ceccoli et al. compared PA patients (46 261 
with APA and 70 with BAH) with 110 EH patients, finding significant increases in PTH levels and 262 
urinary Ca++ excretion, and decreased serum Ca++ levels (with comparable vitamin D concentrations) 263 
[85]. Interesting, PTH levels were higher in patients with APA than in those with BAH [85]. Similarly 264 
Pilz et al. showed higher PTH levels in a small group of patients with PA (5 APA and 5 BAH) 265 
compared to 182 with EH; moreover, they observed that the normalization of PTH levels was more 266 
pronounced in patients operated for APA than those treated with MRA for BAH [86]. It is important to 267 
note that in both studies the PA group had significantly higher blood pressure than the EH group, and 268 
that arterial hypertension itself can increase urinary Ca++ excretion with consequent secondary 269 
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hyperparathyroidism [89]. Nevertheless, a larger observational study demonstrated higher urinary Ca++ 270 
excretion, lower serum Ca++ levels and higher PTH levels in 73 patients with PA in comparison to 73 271 
patients with EH and 40 healthy controls [64], without differences in blood pressure between PA and 272 
EH groups, suggesting  that aldosterone itself may be involved in the stimulation of PTH secretion in 273 
PA. No differences were seen in anthropometric and biochemical characteristics between patients with 274 
APA and BAH [64]. 275 
Another observational study comparing 105 consecutive patients with hypertension, of whom 44 with 276 
APA and 61 with EH, showed that in the APA group there were significantly higher plasma PTH 277 
levels compared to the EH group (P<0.001), despite similar urinary Ca++ excretion and vitamin D 278 
levels [87]. Similar to previous studies, PTH levels were normalized in patients with APA after 279 
adrenalectomy. Moreover, the authors demonstrated the expression of the PTH receptor, at mRNA and 280 
protein levels, in APA tissues and speculated that PTH, by acting on these receptors, may contribute to 281 
hyperaldosteronism despite the suppression of the angiotensin-renin system [87].  282 
Very recently, Salcuni et al. observed a higher prevalence of PA in a group of 322 consecutive 283 
subjects screened for osteoporosis who were not taking drugs affecting bone and mineral metabolism 284 
and who had no prior diagnosis of secondary osteoporosis, compared to a non-osteoporotic control 285 
group (5.2% vs 0.9%, P=0.066). The prevalence of PA was higher still in those who also had 286 
osteoporosis and hypertension (13.9%), fracture and hypertension (14.8%), fracture and hypercalciuria 287 
(11.1%), and osteoporosis, hypertension and hypercalciuria (26.1%), emphasizing the potential 288 
interplay between PA and bone [88]. In this study, osteoporosis was associated with PA (OR=10.42; 289 
95% CI 1.21-90.91), as well as age (OR=1.06; 95% CI 1.03-1.09) and BMI (OR=1.11; 95% CI 1.05-290 
1.17), but not with EH (OR=1.23; 95% CI 0.72-2.1) [88].  291 
Another recent study including 56 PA patients, 16 of whom had APA, and 56 matched healthy 292 
controls identified PA as a risk factor for vertebral fractures independently of blood pressure, glycated 293 
hemoglobin and lipid levels [65]. There were no differences in the vertebral fracture rate in patients 294 
with APA in comparison to those with BAH, despite higher aldosterone plasma levels in patients with 295 
APA. Contrary to previous observational studies [63,64,88], there were no significant differences in 296 
PTH levels and BMD in PA patients compared to controls [65]. This discrepancy could be due to the 297 
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design of the study, which focused on vertebral and not cortical bone [65]. A large population-based 298 
study suggested that PA was associated with higher risk of bone fracture; however, a reduced risk of 299 
fracture in women with both APA or BAH after MRA treatment was not observed, a result which 300 
might reflect the duration of disease [66]. 301 
However, similar to what is observed in autonomous cortisol secretion, the majority of data regarding 302 
PA and bone metabolism came from observational studies of a small cohort of patients evaluated in a 303 
single center. Multicenter observational studies and randomized interventional studies, which 304 
investigate the efficacy of MRA or adrenalectomy for the prevention of osteoporosis, are urgently 305 
needed. 306 
Very recent data suggest the potential role of co-secretion of mild glucocorticoid excess in the 307 
development of comorbidities in patients with PA. Using mass spectrometry-based analysis of the 24-h 308 
urinary steroid metabolic profiling a concomitant presence of mild glucocorticoid metabolite excess 309 
was demonstrated in a large proportion of patients with PA (provocatively termed by the authors as 310 
‘Connshing’s’ syndrome) [14]. Interesting, in the group of patients with co-secretion of aldosterone 311 
and cortisol, metabolic parameters such as increased BMI, insulin resistance, diastolic blood pressure, 312 
waist circumference and high-density lipoprotein were associated with cortisol levels and not with 313 
aldosterone levels [14]. Arlt et al. suggested that the co-secretion of cortisol in patients with PA may 314 
contribute in the pathogenesis of co-morbidities observed in these patients, including osteoporosis 315 
[90,14]. However, prospective randomized studies are needed to confirm this result, and to assess 316 
whether those patients with PA identified as having the glucocorticoid-rich metabolic profile but who 317 
do not undergo surgery, need glucocorticoid antagonist in addition to MRA to counteract the adverse 318 
metabolic risk [14].  319 
 320 
Conclusion and implications for management. 321 
Adrenocortical incidentalomas constitute a common clinical problem with a prevalence of up to 10% 322 
in elderly [1-4], mostly being represented by benign ACA and often being associated with 323 
corticosteroid excess [1,2,7-9]. 324 
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Several observational studies have shown that ACA with autonomous cortisol hypersecretion is more 325 
prevalent than expected in patients with osteopenia and osteoporosis and that the autonomous cortisol 326 
hypersecretion is associated with accelerated bone loss and increased incidence of vertebral fractures 327 
[49-51]. Similarly, hyperaldosteronism is associated with a higher prevalence of osteoporosis 328 
[63,64,66,65,88,74]. Contrary to what is known about glucocorticoid action, the effects of aldosterone 329 
on bone metabolism are less well understood and seem mostly due to an indirect effect through the 330 
increase of urinary Ca++ excretion, leading to compensatory secondary hyperparathyroidism 331 
[85,64,63,61]. However, recent data using urinary steroid metabolic profiling, has shown a mild 332 
cortisol co-secretion in a subgroup of patients with APA and that it may account for some of the 333 
metabolic abnormalities seen in these patients, including osteoporosis [14,90]. 334 
The recent European Society of Endocrinology (ESE) / European Network for the Study of Adrenal 335 
Tumors (ENSAT) guidelines suggest screening of patients with ACA and autonomous cortisol 336 
secretion for vertebral fractures at least once at the time of diagnosis (by re-evaluation of CT images or 337 
by X-ray), while no consensus was reached by the experts concerning the assessment of BMD with 338 
dual-energy x-ray absorptiometry (DXA) [1]. The data summarized above suggest that BMD may not 339 
be accurate for fracture risk assessment in patients with ACA and autonomous cortisol secretion, and 340 
that TBS may be more useful, or at the very least used in combination.  341 
In everyday clinical practice, patients with unexplained osteoporosis, particularly when associated 342 
with other metabolic symptoms (impaired glucose tolerance, hypertension or hypercalciuria), should 343 
be investigated for the possible presence of adrenal incidentaloma associated with autonomous cortisol 344 
secretion or aldosterone hypersecretion. Thus, patients with ACA and osteopenia, osteoporosis or 345 
vertebral fractures might benefit from therapeutic adrenalectomy or when it is not possible from 346 
specific medical treatment, such as glucocorticoid antagonist therapy or MRA, to mitigate against the 347 
comorbidities due to hormone excess [1,12,14]. Furthermore, it is possible that patients with PA, who 348 
do not undergo surgery, might need also glucocorticoid antagonist in addition to MRA if they have a 349 
glucocorticoid metabolite profile [14]. All these suggestions are derived from observational studies; 350 
more data, especially from prospective, randomized, controlled intervention trials, are needed to 351 
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investigate further the optimum surgical or medical interventions to ameliorate osteoporosis and other 352 
co-morbidities due to ACA associated with autonomous cortisol secretion or hyperaldosteronism. 353 
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Figure legends 676 
Fig. 1 Direct effects of cortisol excess on bone metabolism 677 
Endogenous glucocorticoid excess negatively affect osteoblast, osteocytes and osteoclast, which 678 
expressed glucocorticoid receptors (GRs). These action include an upregulation of peroxisome 679 
proliferator-activated receptor (PPAR)-γ [23] and an inhibition of the wingless (wnt)/β-catenin 680 
signaling pathway [24-26], leading to mesenchymal progenitor cells differentiating preferentially into 681 
adipocyte that results in a decreased number of osteoblasts and in an increasing of osteoblast apoptosis 682 
and a consequent reduction of bone formation [28]. This mechanism is also stimulated by sclerostin 683 
produced by osteocytes [30]. Another key mechanism is the increase of the receptor activator for NF-684 
B ligand (RANKL)/osteoprotegerin (OPG) ratio produced by osteoblasts and osteocytes [32-34] that, 685 
together with the increased macrophage colony-stimulating factor (M-CSF) [36], stimulates 686 
osteoclastogenesis and bone resorption. 687 
 688 
Fig. 2 Mechanisms of action of aldosterone on bone metabolism 689 
Aldosterone excess could affect bone turnover directly by binding mineralcorticoid receptors (MRs) 690 
expressed in osteoclasts, osteocytes and osteoblasts [67]. Furthermore, aldosterone regulate PTH 691 
synthesis and secretion through the MRs expressed in cells of parathyroid glands [69,70]. Indirectly, 692 
aldosterone excess regulates bone metabolism through parathyroid hormone (PTH) and oxidative 693 
stress. Hyperaldosteronism expands the extravascular fluid volume that causes a marked increase of 694 
urinary excretion of calcium (Ca++) and magnesium (Mg++) in the distal tubule of the nephron, with a 695 
progressive reduction of serum Ca++ and Mg++ levels. The resulting hypocalcemia and 696 
hypomagnesemia stimulate the secretion of PTH, with a consequent secondary hyperparathyroidism, 697 
which induces bone resorption and a reduction of the bone mineral density (BMD) [61]. Moreover, 698 
aldosterone excess reduces plasma α1-antiprotease activity and increases lymphocyte hydrogen 699 
peroxide production, promoting a condition of oxidative stress resulting in increased osteoblast and 700 
osteocyte apoptosis, and reduction of bone formation [61,81].  701 
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